MabGalaxy

MabGalaxy develops antibody therapeutics for inflammatory and autoimmune diseases, with scientific operations linked to Cambridge's Babraham Research Campus.

Its discovery approach combines immune-system biology with artificial intelligence to support antibody design and selection. The company aims to shorten the progression from early discovery to preclinical drug candidates.

A participant in the 2025 Accelerate@Babraham cohort, MabGalaxy is an early-stage international biotechnology business developing its therapeutic pipeline.